ArticleAntimicrobial agents and chemotherapy2001
Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans.
Article in Antimicrobial agents and chemotherapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 108 citations in OpenAlex.
- Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants.The Journal of antimicrobial chemotherapy · 2018Trial
- Stress-driven emergence of heritable non-genetic drug resistance.Research square · 2025Article
- Clorgyline Analogs Synergize with Azoles against Drug Efflux inJournal of fungi (Basel, Switzerland) · 2023Article
- Development and applications of a CRISPR activation system for facile genetic overexpression in Candida albicans.G3 (Bethesda, Md.) · 2023Article
- Antifungal Drug Concentration Impacts the Spectrum of Adaptive Mutations in Candida albicans.Molecular biology and evolution · 2023Article
- Copy Number Variation and Allele Ratio Analysis in Candida albicans Using Whole Genome Sequencing Data.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Heterogeneity in the transcriptional response of the human pathogen Aspergillus fumigatus to the antifungal agent caspofungin.Genetics · 2022Article
- Bend or break: how biochemically versatile molecules enable metabolic division of labor in clonal microbial communities.Genetics · 2021Review
- Azole resistance mechanisms in pathogenicAntimicrobial agents and chemotherapy · 2021Article
- Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.Frontiers in cellular and infection microbiology · 2021Review
- Gaining Insights from Candida Biofilm Heterogeneity: One Size Does Not Fit All.Journal of fungi (Basel, Switzerland) · 2018Review
- The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen.Journal of microbiology (Seoul, Korea) · 2016Review
- The ABCs of Candida albicans Multidrug Transporter Cdr1.Eukaryotic cell · 2015Review
- Shift and adapt: the costs and benefits of karyotype variations.Current opinion in microbiology · 2015Review
- Update on Antifungal Drug Resistance.Current clinical microbiology reports · 2015Article
- Inhibitors of the Candida albicans Major Facilitator Superfamily Transporter Mdr1p Responsible for Fluconazole Resistance.PloS one · 2015Article
- Mechanisms of Antifungal Drug Resistance.Cold Spring Harbor perspectives in medicine · 2014Review
- Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis.PloS one · 2014Article
- Increase in resistance to fluconazole and itraconazole in Trichophyton rubrum clinical isolates by sequential passages in vitro under drug pressure.Mycopathologia · 2013Article
- The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
The development of azole resistance in Candida albicans is most problematic in patients with AIDS who receive long courses of drug for therapy or prevention of oral candidiasis. Recently, the rapid development of resistance was noted in other immunosuppressed patients who developed disseminated candidiasis despite fluconazole prophylaxis. One of these series of C. albicans isolates became resistant, with an associated increase in mRNA specific for a CDR ATP-binding cassette transporter efflux pump (K. A. Marr, C. N. Lyons, T. R. Rustad, R. A. Bowden, and T. C. White, Antimicrob. Agents Chemother. 42:2584-2589, 1998). Here we study this series of C. albicans isolates further and examine the mechanism of azole resistance in a second series of C. albicans isolates that caused disseminated infection in a recipient of bone marrow transplantation. The susceptible isolates in both series become resistant to fluconazole after serial growth in the presence of drug, while the resistant isolates in both series become susceptible after serial transfer in the absence of drug. Population analysis of the inducible, transiently resistant isolates reveals a heterogeneous population of fluconazole-susceptible and -resistant cells. We conclude that the rapid development of azole resistance occurs by a mechanism that involves selection of a resistant clone from a heterogeneous population of cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.